Canada markets close in 3 hours 6 minutes

AN2 Therapeutics, Inc. (ANTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0800+0.0600 (+2.97%)
As of 12:54PM EDT. Market open.
Currency in USD

Valuation Measures4

Market Cap (intraday) 60.25M
Enterprise Value -34.99M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.54
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 0.05

Trading Information

Stock Price History

Beta (5Y Monthly) -0.05
52-Week Change 3-60.31%
S&P500 52-Week Change 326.14%
52 Week High 322.2200
52 Week Low 31.9200
50-Day Moving Average 32.6817
200-Day Moving Average 311.5670

Share Statistics

Avg Vol (3 month) 3278.9k
Avg Vol (10 day) 3124.47k
Shares Outstanding 529.83M
Implied Shares Outstanding 629.83M
Float 811.9M
% Held by Insiders 125.17%
% Held by Institutions 169.77%
Shares Short (Apr 30, 2024) 4736.89k
Short Ratio (Apr 30, 2024) 42.51
Short % of Float (Apr 30, 2024) 43.83%
Short % of Shares Outstanding (Apr 30, 2024) 42.47%
Shares Short (prior month Mar 28, 2024) 4272.51k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-36.07%
Return on Equity (ttm)-58.83%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA N/A
Net Income Avi to Common (ttm)-64.73M
Diluted EPS (ttm)-2.5100
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)107.3M
Total Cash Per Share (mrq)3.6
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)7.87
Book Value Per Share (mrq)4.19

Cash Flow Statement

Operating Cash Flow (ttm)-53.29M
Levered Free Cash Flow (ttm)-28.85M